Kilitch Drugs Targets ₹1,000 Cr Revenue with New Khopoli Plant & Global Expansion

Mumbai-based pharma company Kilitch Drugs (India) Ltd. is aiming for a big leap—from its current ₹180 crore revenue to ₹1,000 crore over the next 3–4 years. This growth will be powered by a new plant, expansion into regulated markets, and a strong foothold in Africa. Growth Engine: Khopoli Facility • Investment: ₹125 crore in a 15-acre greenfield plant at Khopoli, Maharashtra • Timeline: Operations to begin by Q3FY25 • Capabilities: Will produce nutraceuticals, injectables, eye drops, and oral solid dosage forms • Global Standards: EU & USFDA compliant—key to entering regulated markets by FY28–29 • Goal: Bring in-house 60% of outsourced production → cost savings + margin boost Financial Impact: • FY25 Profit Target: ₹31 crore • Current EBITDA Margin: 17% (expected to improve post-expansion) • FY26: Transition year (slightly subdued) • FY27 Onwards: Higher margins, new products, and full capacity utilisation • Revenue Growth Target: 70–75% during ramp-up phase Africa: Kilitch’s Power Market • Operates in 38 African countries • Strong front-end setup; local manufacturing edge • Top 3 Brand in West Africa with paracetamol effervescent tablets (Roipar) • Ethiopia plant: Largest injectable cephalosporin unit in East Africa • Won a government tender—boost to FY26 revenue Stock Market View: • Clear Long-Term Vision: Five-fold revenue ambition with timelines and execution plan • Capex-Fuelled Margin Expansion: Lower dependency on outsourcing improves profitability • Global Market Access: US & EU compliance opens doors to higher-value markets • Africa Dominance: Sustained growth from a market many peers exited With steady execution, Kilitch Drugs could see re-rating potential in the stock, especially from FY27 when operating leverage, exports, and product mix start to reflect in financials.